Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma

BACKGROUND: Zolbetuximab plus first-line EOX (epirubicin, oxaliplatin, capecitabine; ZOL/EOX) significantly prolonged progression-free survival and overall survival in the FAST trial vs EOX alone. We report the patient-reported outcomes (PROs) of FAST in patients with advanced gastroesophageal adeno...

Descripción completa

Detalles Bibliográficos
Autores principales: Lordick, Florian, Al-Batran, Salah-Eddin, Ganguli, Arijit, Morlock, Robert, Sahin, Ugur, Türeci, Özlem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064997/
https://www.ncbi.nlm.nih.gov/pubmed/33755863
http://dx.doi.org/10.1007/s10120-020-01153-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064997/
https://www.ncbi.nlm.nih.gov/pubmed/33755863
http://dx.doi.org/10.1007/s10120-020-01153-6

Ejemplares similares